Baidu
map

Sci Rep:细胞减灭肾切除术围术期使用酪氨酸激酶抑制剂的相关并发症研究

2019-11-11 AlexYang MedSci原创

最近的临床试验调查了在转移性肾细胞癌患者中进行酪氨酸激酶抑制剂(TKIs)和细胞减灭肾切除术(CN)组合治疗的益处。最近,有研究人员在肾细胞肿瘤患者中确定了是否围术期使用TKIs在CN之后能够增加术后并发症。研究包括了627名IV期肾细胞癌患者,他们在2007年到 2010年经历了CN。研究发现,在未调整的分析中,TKI在CN前使用与术后30天内更高的总并发症发生率相关(HR=2.73, 95%C

最近的临床试验调查了在转移性肾细胞癌患者中进行酪氨酸激酶抑制剂(TKIs)和细胞减灭肾切除术(CN)组合治疗的益处。最近,有研究人员在肾细胞肿瘤患者中确定了是否围术期使用TKIs在CN之后能够增加术后并发症。

研究包括了627名IV期肾细胞癌患者,他们在2007年到 2010年经历了CN。研究发现,在未调整的分析中,TKI在CN前使用与术后30天内更高的总并发症发生率相关(HR=2.73, 95%CI: 1.09-6.8)。在多变量分析中,肾切除术后30天内(HR=2.93, 95% CI: 1.17-7.36)和90天内(HR=1.84, 95% CI: 1.02-3.32),围术期TKI使用与更高的术后并发症风险独立相关。另外,肾切除术后30天内(HR=2.41, 95% CI: 1.44-4.02)和90天内(HR=2.23, 95% CI: 1.51-3.29),更高的Charlson共病指数可作为一个独立的风险因子。TKI治疗在术后30天和90天与术后死亡率的增加没有关系。因此,TKI治疗与并发症的增加相关而与CN后总的死亡率无关。

最后,研究人员指出,当使用TKI治疗时,肾外科医生应该注意肾细胞癌患者CN后并发症可能增加的情况。

原始出处:

Filipe L. F. Carvalho, Chaoyi Zheng, Kenneth Witmer et al. Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy. Sci Rep. 24 Oct 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1740669, encodeId=c14c1e4066913, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Sat Sep 05 10:26:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716285, encodeId=b8301e16285ff, content=<a href='/topic/show?id=e9f382466b9' target=_blank style='color:#2F92EE;'>#肾切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82466, encryptionId=e9f382466b9, topicName=肾切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770132196036, createdName=gaoxiaoe, createdTime=Sat Feb 22 02:26:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758177, encodeId=eacc1e5817795, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Feb 20 08:26:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852177, encodeId=c56418521e797, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 10 10:26:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800322, encodeId=c3dc18003221f, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Oct 09 11:26:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Jun 21 07:26:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877215, encodeId=59f818e721549, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat May 30 06:26:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275449, encodeId=0f0a12e544950, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496076, encodeId=50d214960e687, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1740669, encodeId=c14c1e4066913, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Sat Sep 05 10:26:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716285, encodeId=b8301e16285ff, content=<a href='/topic/show?id=e9f382466b9' target=_blank style='color:#2F92EE;'>#肾切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82466, encryptionId=e9f382466b9, topicName=肾切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770132196036, createdName=gaoxiaoe, createdTime=Sat Feb 22 02:26:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758177, encodeId=eacc1e5817795, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Feb 20 08:26:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852177, encodeId=c56418521e797, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 10 10:26:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800322, encodeId=c3dc18003221f, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Oct 09 11:26:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Jun 21 07:26:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877215, encodeId=59f818e721549, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat May 30 06:26:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275449, encodeId=0f0a12e544950, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496076, encodeId=50d214960e687, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1740669, encodeId=c14c1e4066913, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Sat Sep 05 10:26:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716285, encodeId=b8301e16285ff, content=<a href='/topic/show?id=e9f382466b9' target=_blank style='color:#2F92EE;'>#肾切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82466, encryptionId=e9f382466b9, topicName=肾切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770132196036, createdName=gaoxiaoe, createdTime=Sat Feb 22 02:26:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758177, encodeId=eacc1e5817795, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Feb 20 08:26:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852177, encodeId=c56418521e797, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 10 10:26:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800322, encodeId=c3dc18003221f, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Oct 09 11:26:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Jun 21 07:26:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877215, encodeId=59f818e721549, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat May 30 06:26:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275449, encodeId=0f0a12e544950, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496076, encodeId=50d214960e687, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=)]
    2020-02-20 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1740669, encodeId=c14c1e4066913, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Sat Sep 05 10:26:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716285, encodeId=b8301e16285ff, content=<a href='/topic/show?id=e9f382466b9' target=_blank style='color:#2F92EE;'>#肾切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82466, encryptionId=e9f382466b9, topicName=肾切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770132196036, createdName=gaoxiaoe, createdTime=Sat Feb 22 02:26:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758177, encodeId=eacc1e5817795, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Feb 20 08:26:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852177, encodeId=c56418521e797, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 10 10:26:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800322, encodeId=c3dc18003221f, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Oct 09 11:26:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Jun 21 07:26:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877215, encodeId=59f818e721549, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat May 30 06:26:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275449, encodeId=0f0a12e544950, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496076, encodeId=50d214960e687, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=)]
    2020-01-10 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=1740669, encodeId=c14c1e4066913, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Sat Sep 05 10:26:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716285, encodeId=b8301e16285ff, content=<a href='/topic/show?id=e9f382466b9' target=_blank style='color:#2F92EE;'>#肾切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82466, encryptionId=e9f382466b9, topicName=肾切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770132196036, createdName=gaoxiaoe, createdTime=Sat Feb 22 02:26:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758177, encodeId=eacc1e5817795, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Feb 20 08:26:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852177, encodeId=c56418521e797, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 10 10:26:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800322, encodeId=c3dc18003221f, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Oct 09 11:26:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Jun 21 07:26:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877215, encodeId=59f818e721549, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat May 30 06:26:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275449, encodeId=0f0a12e544950, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496076, encodeId=50d214960e687, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1740669, encodeId=c14c1e4066913, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Sat Sep 05 10:26:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716285, encodeId=b8301e16285ff, content=<a href='/topic/show?id=e9f382466b9' target=_blank style='color:#2F92EE;'>#肾切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82466, encryptionId=e9f382466b9, topicName=肾切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770132196036, createdName=gaoxiaoe, createdTime=Sat Feb 22 02:26:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758177, encodeId=eacc1e5817795, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Feb 20 08:26:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852177, encodeId=c56418521e797, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 10 10:26:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800322, encodeId=c3dc18003221f, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Oct 09 11:26:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Jun 21 07:26:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877215, encodeId=59f818e721549, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat May 30 06:26:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275449, encodeId=0f0a12e544950, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496076, encodeId=50d214960e687, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1740669, encodeId=c14c1e4066913, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Sat Sep 05 10:26:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716285, encodeId=b8301e16285ff, content=<a href='/topic/show?id=e9f382466b9' target=_blank style='color:#2F92EE;'>#肾切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82466, encryptionId=e9f382466b9, topicName=肾切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770132196036, createdName=gaoxiaoe, createdTime=Sat Feb 22 02:26:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758177, encodeId=eacc1e5817795, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Feb 20 08:26:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852177, encodeId=c56418521e797, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 10 10:26:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800322, encodeId=c3dc18003221f, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Oct 09 11:26:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Jun 21 07:26:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877215, encodeId=59f818e721549, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat May 30 06:26:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275449, encodeId=0f0a12e544950, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496076, encodeId=50d214960e687, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1740669, encodeId=c14c1e4066913, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Sat Sep 05 10:26:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716285, encodeId=b8301e16285ff, content=<a href='/topic/show?id=e9f382466b9' target=_blank style='color:#2F92EE;'>#肾切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82466, encryptionId=e9f382466b9, topicName=肾切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770132196036, createdName=gaoxiaoe, createdTime=Sat Feb 22 02:26:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758177, encodeId=eacc1e5817795, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Feb 20 08:26:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852177, encodeId=c56418521e797, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 10 10:26:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800322, encodeId=c3dc18003221f, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Oct 09 11:26:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Jun 21 07:26:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877215, encodeId=59f818e721549, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat May 30 06:26:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275449, encodeId=0f0a12e544950, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496076, encodeId=50d214960e687, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1740669, encodeId=c14c1e4066913, content=<a href='/topic/show?id=fd0a95511dd' target=_blank style='color:#2F92EE;'>#酪氨酸激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95511, encryptionId=fd0a95511dd, topicName=酪氨酸激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22af34798690, createdName=luckyshitiancai_42705695, createdTime=Sat Sep 05 10:26:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716285, encodeId=b8301e16285ff, content=<a href='/topic/show?id=e9f382466b9' target=_blank style='color:#2F92EE;'>#肾切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82466, encryptionId=e9f382466b9, topicName=肾切除术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=770132196036, createdName=gaoxiaoe, createdTime=Sat Feb 22 02:26:00 CST 2020, time=2020-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758177, encodeId=eacc1e5817795, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Thu Feb 20 08:26:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852177, encodeId=c56418521e797, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 10 10:26:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800322, encodeId=c3dc18003221f, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Fri Oct 09 11:26:00 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039905, encodeId=507a2039905aa, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66859, encryptionId=f7526685963, topicName=激酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Sun Jun 21 07:26:00 CST 2020, time=2020-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877215, encodeId=59f818e721549, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat May 30 06:26:00 CST 2020, time=2020-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275449, encodeId=0f0a12e544950, content=<a href='/topic/show?id=6a39406551e' target=_blank style='color:#2F92EE;'>#围术期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40655, encryptionId=6a39406551e, topicName=围术期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496076, encodeId=50d214960e687, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Wed Nov 13 12:26:00 CST 2019, time=2019-11-13, status=1, ipAttribution=)]
    2019-11-13 redcrab

相关资讯

Oncogene:靶向加压素2型受体治疗肾细胞癌研究

精氨酸后叶加压素(AVP)和其2型受体(V2R)在肾脏的盐分和水分稳态调控中具有必要的作用。体外试验中,V2R激活能够刺激肾细胞肿瘤(RCC)细胞系的增殖。最近,有研究人员在人类RCC肿瘤中调查了V2R表达和活性,以及其在RCC肿瘤生长中的作用。研究人员通过对癌症基因组数据库(TCGA)的调查,人类RCC肿瘤组织芯片的分析以及cDNA和肿瘤组织样本分析阐释了V2R表达和在透明细胞RCC(ccRCC

Nat Commun:肾细胞癌中PAX8能够通过增强子激活代谢基因

转录因子网络塑造了基因表达过程,并且负责正常的细胞身份和致病状态。最近,有研究人员使用核心调控环路分析(CRC)鉴定了肾细胞癌(RCC)细胞中的一个候选致癌基因PAX8。大规模功能基因组验证筛选确定了PAX8的功能沉默能够导致RCC细胞系增殖减弱。PAX8依赖的顺反组表观遗传分析阐释了PAX8具有活性增强子元件,并控制各种代谢相关途径基因的表达。研究人员选择了铁氧化酶血浆铜蓝蛋白(CP)作为模范基

Cancer Gene Therapy:CRHBP能够抑制肾细胞肿瘤的恶化

肾细胞肿瘤(RCC)患者经常会发展成为药物抗性,并且由于对药物的不敏感性产生了不良的预后。然而,RCC潜在的机制仍旧不清楚。最近,有研究人员进行了对癌症基因组数据库和基因表达综合数据库进行了综合的分析。研究发现,3个基因(CRHBP、RAB25和PSAT1)在ccRCC中可以作为可能的生物标记,并在4个独立的群体中得到了验证。另外,ccRCC患者肿瘤组织中的CRHBP表达减少,并且在TCGA cc

Eur Urol:转移肾细胞癌的一线肿瘤免疫联合疗法疗效分析

在转移性肾细胞癌(mRCC)中,近期的数据显示了一线药物易普利姆玛与纳武单抗(ipi-nivo)联合和免疫肿瘤(IO)/血管内皮生长因子(VEGF)抑制剂联合治疗的疗效情况。但是这些治疗策略之间的比较性数据仍旧有限。最近,有研究人员比较了ipi-nivo与IO-VEGF (IOVE)在mRCC中的疗效比较情况,并阐释了实践模式和二线疗法的疗效情况。研究总共有113名患者接受了IOVE联合疗法,75

2019 ESMO|辅助到晚期一线治疗,同样需对肾细胞癌患者进行精细化的分层管理

2019年欧洲肿瘤内科学会(ESMO)年会在西班牙巴塞罗那盛大召开,众多最新研究结果公布,再次吸引全世界肿瘤专家学者的关注。过往几年,在ESMO大会上,肾癌领域重磅研究不断,本次大会上又有哪些最新进展呢?在会议现场,有幸采访到北京大学肿瘤医院的盛锡楠教授,介绍肾癌领域的最新进展,同时探讨当前靶向治疗在肾癌中的地位。

Sci Rep:Myoferlin沉默能够抑制VEGFR2介导的转移透明细胞肾细胞癌增殖

最近,一种靶向血管内皮生长因子受体(VEGFR)的药物-雷莫芦单抗获得临床批准;因此,有研究人员在透明细胞肾细胞癌(CCRCC)中评估了VEGFR2的表达并预测了在肿瘤恶化中的作用。由于目前在治疗恶性肾细胞癌中没有更多的选择,抗VEGFR2疗法也许是有用的。Myoferlin (MYOF)大小为230 kDa的跨膜蛋白,且具多个C2结构域,能够在质膜修复、融合和内吞作用中起作用,并在一些浸润癌症细

Baidu
map
Baidu
map
Baidu
map